Hershey Co vs Humana Inc — how do they compare? Hershey Co trades at $183 (market cap $36.56B), while Humana Inc trades at $388.05 (market cap $44.77B). The key difference: Humana Inc is the larger of the two by market cap, and Hershey Co pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| HSY | HUM | |
|---|---|---|
Market Cap | $36.56B | $44.77B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $409.42 |
52-Week Low | $162.31 | $163.67 |
Enterprise Value | $41.70B | $52.12B |
Dividend Yield | 3.19% | 0.95% |
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $184.19, up 0.79% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth remains steady at $11.69 billion for 2025. Technical indicators show bullish momentum with the current price near resistance at $184, supported by positive moving average signals. The company maintains robust profitability with 38.38% gross margins and 32.81% ROE, though net income declined to $883 million in 2025 from previous highs.
HSY presents a favorable risk-reward profile with analyst consensus target of $196.78 offering 7% upside potential. Recent margin recovery from favorable cocoa contracts and dividend growth support bullish sentiment, though volume declines and competitive pressures in salty snacks remain concerns. With 68.57% of analysts maintaining Hold ratings, the stock offers steady growth potential but requires monitoring of consumer demand trends and input cost management.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Trailing returns across standard periods
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →